| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
COX-1 COX-2
Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2). 4,4'-Dihydroxy-2,6-dimethoxydihydrochalcone exhibits inhibitory activity against both COX-1 and COX-2 enzymes, demonstrating potent but non-selective inhibition. By blocking COX activity, it reduces the production of pro-inflammatory prostaglandins from arachidonic acid. |
|---|---|
| ln Vitro |
In vitro, 4,4'-Dihydroxy-2,6-dimethoxydihydrochalcone exhibits COX-1 and COX-2 inhibitory activity. Related stilbenoids from the same plant source show IC50 values ranging from 1.29 to 4.92 uM for COX inhibition. The dihydrochalcone itself is reported to inhibit both COX-1 and COX-2, with anti-inflammatory effects observed in biochemical assays.
|
| ln Vivo |
No detailed in vivo studies for 4,4'-Dihydroxy-2,6-dimethoxydihydrochalcone alone are publicly available. Given its COX inhibitory activity in vitro, it would be expected to reduce inflammation in standard in vivo models such as carrageenan-induced paw edema or arachidonic acid-induced ear edema, though this remains to be validated.
|
| Enzyme Assay |
A COX inhibition assay is performed using purified ovine COX-1 and human recombinant COX-2 enzymes. The enzymes are pre-incubated with serially diluted 4,4'-Dihydroxy-2,6-dimethoxydihydrochalcone (0.1-1000 uM) for 10 minutes at room temperature. Arachidonic acid (100 uM) is added, and the reaction proceeds for 2 minutes at 37degC. The reaction is stopped with 1 M HCl, and PGE2 production is quantified by ELISA. The IC50 for each isoform is calculated.
|
| Cell Assay |
For in vitro cellular assays, murine macrophages (RAW 264.7) are stimulated with lipopolysaccharide (LPS, 1 ug/mL) to induce COX-2 expression. Cells are treated with serially diluted 4,4'-Dihydroxy-2,6-dimethoxydihydrochalcone (0.1-1000 uM) for 24 hours. Supernatant PGE2 and TNF-alpha levels are measured by ELISA. Cell viability is assessed using an MTT or CellTiter-Glo assay to rule out cytotoxicity. Nitric oxide (NO) production is measured using the Griess reagent.
|
| Animal Protocol |
No published in vivo animal studies are available for this specific compound. For research use, the arachidonic acid-induced mouse ear edema model can be used. Male CD-1 mice (n=6 per group) receive an intradermal injection of arachidonic acid (2 mg/ear in acetone) into the right ear. The compound is administered orally or intraperitoneally at doses of 5-50 mg/kg, 30 minutes before arachidonic acid challenge. After 1 hour, ear punch biopsies are taken, and edema is measured by weight difference between treated and control ears.
|
| ADME/Pharmacokinetics |
4,4'-Dihydroxy-2,6-dimethoxydihydrochalcone has a molecular weight of 302.32 g/mol and a formula of C17H18O5. It is soluble in DMSO (100 mg/mL) and ethanol. Detailed in vivo PK parameters (e.g., half-life, Cmax, oral bioavailability) are not publicly available. As a flavonoid, it is likely to undergo extensive phase II metabolism (glucuronidation, sulfation) and may have moderate oral bioavailability.
|
| Toxicity/Toxicokinetics |
Detailed toxicological data for 4,4'-Dihydroxy-2,6-dimethoxydihydrochalcone are not publicly available. Based on the general safety profile of dietary flavonoids, it is expected to be well-tolerated at moderate doses. High doses may cause mild gastrointestinal disturbances or drug-drug interactions due to inhibition of drug-metabolizing enzymes. No severe toxicities have been reported.
|
| References | |
| Additional Infomation |
It has been reported that 4,4'-dihydroxy-2,6-dimethoxydihydrochalcone is found in dragon blood trees and soybeans, and there is relevant data available.
4,4'-Dihydroxy-2,6-dimethoxydihydrochalcone is a research-grade compound not approved for clinical use. It is a natural product isolated from Dracaena loureiri and is used to study the anti-inflammatory effects of flavonoids, particularly their inhibition of COX-1 and COX-2. This product is for laboratory research purposes only, not for human therapeutic use. |
| Molecular Formula |
C17H18O5
|
|---|---|
| Molecular Weight |
302.32
|
| Exact Mass |
302.115
|
| CAS # |
151752-08-8
|
| PubChem CID |
10424988
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
532.7±50.0 °C at 760 mmHg
|
| Flash Point |
196.7±23.6 °C
|
| Vapour Pressure |
0.0±1.5 mmHg at 25°C
|
| Index of Refraction |
1.594
|
| LogP |
2.8
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
22
|
| Complexity |
337
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC1=C(CCC(=O)C2=CC=C(C=C2)O)C(=CC(=C1)O)OC
|
| InChi Key |
WRSUVSOOJHAIRI-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C17H18O5/c1-21-16-9-13(19)10-17(22-2)14(16)7-8-15(20)11-3-5-12(18)6-4-11/h3-6,9-10,18-19H,7-8H2,1-2H3
|
| Chemical Name |
3-(4-hydroxy-2,6-dimethoxyphenyl)-1-(4-hydroxyphenyl)propan-1-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3078 mL | 16.5388 mL | 33.0775 mL | |
| 5 mM | 0.6616 mL | 3.3078 mL | 6.6155 mL | |
| 10 mM | 0.3308 mL | 1.6539 mL | 3.3078 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
